Tel :
+33(0)5 55 05 69 83
Courriel :
secretariat.cic@chu-limoges.fr
Adresse
2 Av. Martin Luther King, Limoges

PUBLICATIONS

2025 - 2024 - 2023 - 2022

Association of Staphylococcus aureus bacteriuria and prevalence of infective endocarditis in the emergency department. (ENDOSTAPH Study).

LAFON T, BAISSE A, BARRAUD O, FRANÇOIS B, VIGNON P.

European Journal of Emergency Medicine. 2022 ; doi: 10.1097/MEJ.0000000000000840
A Randomised trial of anti-GM-CSF Otilimab in severe COVID-19 pneumonia (OSCAR Study).

PATEL J, BASS D, BEISHUIZEN A, BOCCA RUIZ X, BOUGHANMI H, CAHN A, COLOMBO H, CRINER GJ, DAVY K, DE-MIGUEL-DÍEZ J, DORESKI PA, FERNANDES S, FRANÇOIS B, GUPTA A, HANROTT K, HATLEN T, INMAN D, ISAACS JD, JARVIS E, KOSTINA N, KROPOTINA T, LACHERADE JC, LAKSHMINARAYANAN D, MARTINEZ-AYALA P, MCEVOY C, MEZIANI F, MONCHI M, MUKHERJEE S, MUÑOZ-BERMÚDEZ R, NEISEN J, O'SHEA C, PLANTEFEVE G, SCHIFANO L, SCHWAB LE, SHAHID Z, SHIRANO M, SMITH JE, SPRINZ E, SUMMERS C, TERZI N, TIDSWELL MA, TREFILOVA Y, WILLIAMSON R, WYNCOLL D, LAYTON M.

European Respiratory Journal. 2022 ; https://doi.org/10.1183/13993003.01870-2021
Echocardiography findings in COVID-19 patients admitted to intensive care units: a multi-national observational study (the ECHO-COVID study).

HUANG S, VIGNON P, MEKONTSO-DESSAP A, TRAN S, PRAT G, CHEW M, BALIK M, SANFILIPPO F, BANAUCH G, CLAU-TERRE F, MORELLI A, DE BACKER D, CHOLLEY B, SLAMA M, CHARRON C, GOUDELIN M, BAGATE F, BAILLY P, BLIXT PJ, MASI P, EVRARD B, ORDE S, MAYO P, MCLEAN AS, VIEILLARD-BARON A; ECHO-COVID Group.

Intensive Care Medicicne. Jun 2022 ; DOI: 10.1007/s00134-022-06685-2
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial (MARIBAVIR SHP620-303 / SOLSTICE)

AVERY RK, ALAIN S, ALEXANDER BD, BLUMBERG EA, CHEMALY RF, CORDONNIER C, DUARTE RF, FLORESCU DF, KAMAR N, KUMAR D, MAERTENS J, MARTY FM, PAPANICOLAOU GA, SILVEIRA FP, WITZKE O, WU J, SUNDBERG AK, FOURNIER M; SOLSTICE TRIAL INVESTIGATORS.

Clinical Infectious Diseases. Sep 2022 ; doi: 10.1093/cid/ciab988
Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial (EVADE Study)

CHASTRE J, FRANÇOIS B, BOURGEOIS M, KOMNOS A, FERRER R, RAHAV G, DE SCHRYVER N, LEPAPE A, KOKSAL I, LUYT CE, SÁNCHEZ-GARCÍA M, TORRES A, EGGIMANN P, KOULENTI D, HOLLAND TL, ALI O, SHOEMAKER K, REN P, SAUSER J, RUZIN A, TABOR DE, AKHGAR A, WU Y, JIANG Y, DIGIANDOMENICO A, COLBERT S, VANDAMME D, COENJAERTS F, MALHOTRA-KUMAR S, TIMBERMONT L, OLIVER A, BARRAUD O, BELLAMY T, BONTEN M, GOOSSENS H, REISNER C, ESSER MT, JAFRI HS; COMBACTE-MAGNET EVADE STUDY GROUP.

Critical Care. Nov 2022 ; DOI: 10.1186/s13054-022-04204-9